Adicet Bio, Inc. (ACET) stock
ACETNasdaqPharmaceutical PreparationsFiscal year ends December 26
$2.93−0.06 (-2.01%)
Close on Nov 12, 2026Market cap $27.43MP/E –Yield –
Adicet Bio r&d expenses
Research and development expenses are spending on new products and technology.
Adicet Bio's R&D Expenses for the twelve months ending Sep 30, 2026 was $76.60M, down 21.3% year over year. For fiscal 2025 it was $99.13M, down 0.2% from the year before. The highest annual figure on record is $106.04M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $99.13M | -0.2% |
| FY2024 | Dec 31, 2024 | $99.32M | -6.3% |
| FY2023 | Dec 31, 2023 | $106.04M | +48.8% |
| FY2022 | Dec 31, 2022 | $71.25M | +45.6% |
| FY2021 | Dec 31, 2021 | $48.94M | +42.5% |
| FY2020 | Dec 31, 2020 | $34.33M | +44.9% |
| FY2019 | Dec 31, 2019 | $23.69M | +61.0% |
| FY2018 | Dec 31, 2018 | $14.72M | -12.6% |
| FY2017 | Dec 31, 2017 | $16.84M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $15.63M | -31.6% |
| Q2 FY2026 | Jun 30, 2026 | $18.45M | -35.1% |
| Q1 FY2026 | Mar 31, 2026 | $17.49M | -23.3% |
| Q4 FY2025 | Dec 31, 2025 | $25.04M | +7.6% |
| Q3 FY2025 | Sep 30, 2025 | $22.85M | -13.0% |
| Q2 FY2025 | Jun 30, 2025 | $28.42M | +9.7% |
| Q1 FY2025 | Mar 31, 2025 | $22.81M | -4.5% |
| Q4 FY2024 | Dec 31, 2024 | $23.27M | -6.0% |
| Q3 FY2024 | Sep 30, 2024 | $26.25M | +0.3% |
| Q2 FY2024 | Jun 30, 2024 | $25.90M | -8.7% |
| Q1 FY2024 | Mar 31, 2024 | $23.90M | -10.7% |
| Q4 FY2023 | Dec 31, 2023 | $24.76M | -1.0% |
| Q3 FY2023 | Sep 30, 2023 | $26.17M | +57.9% |
| Q2 FY2023 | Jun 30, 2023 | $28.36M | +75.3% |
| Q1 FY2023 | Mar 31, 2023 | $26.76M | +98.4% |
| Q4 FY2022 | Dec 31, 2022 | $25.02M | +70.7% |
| Q3 FY2022 | Sep 30, 2022 | $16.57M | +38.9% |
| Q2 FY2022 | Jun 30, 2022 | $16.18M | +52.4% |
| Q1 FY2022 | Mar 31, 2022 | $13.48M | +14.8% |
| Q4 FY2021 | Dec 31, 2021 | $14.66M | +51.4% |
| Q3 FY2021 | Sep 30, 2021 | $11.93M | +33.4% |
| Q2 FY2021 | Jun 30, 2021 | $10.62M | +22.4% |
| Q1 FY2021 | Mar 31, 2021 | $11.74M | +67.0% |
| Q4 FY2020 | Dec 31, 2020 | $9.68M | +48.4% |
| Q3 FY2020 | Sep 30, 2020 | $8.94M | +41.2% |
| Q2 FY2020 | Jun 30, 2020 | $8.68M | -47.6% |
| Q1 FY2020 | Mar 31, 2020 | $7.03M | -20.5% |
| Q4 FY2019 | Dec 31, 2019 | $6.52M | +50.0% |
| Q3 FY2019 | Sep 30, 2019 | $6.33M | -6.4% |
| Q2 FY2019 | Jun 30, 2019 | $16.55M | +39.7% |
| Q1 FY2019 | Mar 31, 2019 | $8.85M | +9.2% |
| Q4 FY2018 | Dec 31, 2018 | $4.35M | -36.0% |
| Q3 FY2018 | Sep 30, 2018 | $6.77M | +103.0% |
| Q2 FY2018 | Jun 30, 2018 | $11.85M | +246.3% |
| Q1 FY2018 | Mar 31, 2018 | $8.11M | +146.1% |
| Q4 FY2017 | Dec 31, 2017 | $6.79M | – |
| Q3 FY2017 | Sep 30, 2017 | $3.33M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.42M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.29M | – |
See a number that looks wrong?